1.Pulmonary alveolar proteinosis in a 15-year-old girl.
Yechan KYUNG ; Jihyun KIM ; Hong Kwan KIM ; Joungho HAN ; Kangmo AHN
Allergy, Asthma & Respiratory Disease 2015;3(1):86-89
Pulmonary alveolar proteinosis (PAP) is a diffuse lung disease characterized by the accumulation of lipoproteins derived from surfactants in the distal air space. The lack of granulocyte macrophage colony-stimulating factor is believed to contribute to macrophage dysfunction and the impaired processing of surfactants. Because the prevalence of PAP in the general population is less than 1 in 200,000, and the typical age at presentation is 35 to 50 years, PAP is a very rare disease in children. To the best of our knowledge, there has been no Korean report on PAP in children. We describe here a patient who was diagnosed with PAP at the aged 15 years.
Adolescent*
;
Child
;
Female
;
Granulocytes
;
Humans
;
Lipoproteins
;
Lung Diseases
;
Macrophage Colony-Stimulating Factor
;
Macrophages
;
Prevalence
;
Pulmonary Alveolar Proteinosis*
;
Rare Diseases
;
Surface-Active Agents
2.Birth seasonality in Korean Prader-Willi syndrome with chromosome 15 microdeletion.
Aram YANG ; Yeon Hee LEE ; Soon Young NAM ; Yu Ju JEONG ; Yechan KYUNG ; Rimm HUH ; Jieun LEE ; Younghee KWUN ; Sung Yoon CHO ; Dong Kyu JIN
Annals of Pediatric Endocrinology & Metabolism 2015;20(1):40-45
PURPOSE: Prader-Willi syndrome (PWS) is a well-known genetic disorder, and microdeletion on chromosome 15 is the most common causal mechanism. Several previous studies have suggested that various environmental factors might be related to the pathogenesis of microdeletion in PWS. In this study, we investigated birth seasonality in Korean PWS. METHODS: A total of 211 PWS patients born from 1980 to 2014 were diagnosed by methylation polymerase chain reaction at Samsung Medical Center. Of the 211 patients, 138 were born from 2000-2013. Among them, the 74 patients of a deletion group and the 22 patients of a maternal uniparental disomy (UPD) group were compared with general populations born from 2000 using the Walter and Elwood method and cosinor analysis. RESULTS: There was no statistical significance in seasonal variation in births of the total 211 patients with PWS (chi2=7.2522, P=0.2982). However, a significant difference was found in the monthly variation between PWS with the deletion group and the at-risk general population (P<0.05). In the cosinor model, the peak month of birth for PWS patients in the deletion group was January, while the nadir occurred in July, with statistical significance (amplitude=0.23, phase=1.2, low point=7.2). The UPD group showed the peak birth month in spring; however, this result was not statistically significant (chi2=3.39, P=0.1836). CONCLUSION: Correlation with birth seasonality was identified in a deletion group of Korean PWS patients. Further studies are required to identify the mechanism related to seasonal effects of environmental factors on microdeletion on chromosome 15.
Chromosomes, Human, Pair 15*
;
Humans
;
Methylation
;
Parturition*
;
Polymerase Chain Reaction
;
Prader-Willi Syndrome*
;
Seasons*
;
Uniparental Disomy
3.Three cases of oral immunotherapy for IgE-mediated egg allergy
Insung KIM ; Bo Ra LEE ; Yechan KYUNG ; Minyoung JUNG ; Hea-Kyoung YANG ; Minji KIM ; Ji Young LEE ; Jihyun KIM ; Kangmo AHN ; Hye-In JEONG
Allergy, Asthma & Respiratory Disease 2020;8(3):161-164
Food allergy is an immune-mediated adverse reaction that occurs mainly by food ingestion. Some children with food allergies manifest fatal symptoms like anaphylaxis. Oral immunotherapy (OIT) may offer an effective therapeutic modality for persistent and severe forms of food allergies. We report our experience with OIT in 3 patients with IgE-mediated hen’s egg allergy. Our treatment strategy consists of 1–3 days of initial escalation, 47 to 65 weeks of build-up phase, and 1 year of maintenance phase. Lactobacillus plantarum CJLP133, 1×1010 colony-forming unit/day was taken during OIT. As a result, 1 patient achieved successful desensitization, and 1 patient reached maintenance therapy, but did not obtain desensitization. In addition, 1 patient withdrew from treatment due to anxiety symptoms. Despite the limited number of patients, we experienced and herein presented 3 cases of OIT in egg allergy. More trials of OIT need to be performed as a treatment option in Korean children with food allergies.
4.Dietary Diversity during Early Infancy Increases Microbial Diversity and Prevents Egg Allergy in High-Risk Infants
Bo Ra LEE ; Hye-In JUNG ; Su Kyung KIM ; Mijeong KWON ; Hyunmi KIM ; Minyoung JUNG ; Yechan KYUNG ; Byung Eui KIM ; Suk-Joo CHOI ; Soo-Young OH ; Sun-Young BAEK ; Seonwoo KIM ; Jaewoong BAE ; Kangmo AHN ; Jihyun KIM
Immune Network 2022;22(2):e17-
We aimed to investigate associations of dietary diversity (DD) with gut microbial diversity and the development of hen's egg allergy (HEA) in infants. We enrolled 68 infants in a highrisk group and 32 infants in a control group based on a family history of allergic diseases. All infants were followed from birth until 12 months of age. We collected infant feeding data, and DD was defined using 3 measures: the World Health Organization definition of minimum DD, food group diversity, and food allergen diversity. Gut microbiome profiles and expression of cytokines were evaluated by bacterial 16S rRNA sequencing and real-time reverse transcriptase-polymerase chain reaction. High DD scores at 3 and 4 months were associated with a lower risk of developing HEA in the high-risk group, but not in the control group. In the high-risk group, high DD scores at 3, 4, and 5 months of age were associated with an increase in Chao1 index at 6 months. We found that the gene expression of IL-4, IL-5, IL-6, and IL-8 were higher among infants who had lower DD scores compared to those who had higher DD scores in high-risk infants. Additionally, high-risk infants with a higher FAD score at 5 months of age showed a reduced gene expression of IL-13. Increasing DD within 6 months of life may increase gut microbial diversity, and thus reduce the development of HEA in infants with a family history of allergic diseases.
5.Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety.
Hye Won LEE ; Se Rim OH ; Dong Yun KIM ; Yechan JEONG ; Seungtaek KIM ; Beom Kyung KIM ; Seung Up KIM ; Do Young KIM ; Sang Hoon AHN ; Kwang Hyub HAN ; Jun Yong PARK
Gut and Liver 2018;12(3):324-330
BACKGROUND/AIMS: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety of DCV+ASV treatment in Korean patients. METHODS: In total, 363 patients with chronic hepatitis C were treated with DCV+ASV between August 2015 and January 2017. Finally, we analyzed the data of 270 patients who were monitored for at least 12 weeks after the end of treatment. RESULTS: The mean age was 60.7 years, and females predominated (60.4%). Most patients (64.8%) were treatment-naïve, and 56 patients (20.7%) had cirrhosis. Two hundred fifty-seven (95.2%) and 251 (93.0%) patients achieved end-of-treatment responses and sustained virological responses at 12 weeks posttreatment (SVR12), respectively. The SVR12 rates were higher in patients who were < 65 years of age, males, without cirrhosis and had lower HCV RNA levels. All LS values and fibrosis-4 and aspartate aminotransferase-to-platelet ratio index values declined from baseline to the time of assessment of SVR12. CONCLUSIONS: The DCV+ASV therapy resulted in a high SVR12 and improved liver fibrosis; the treatment was well tolerated in patients with genotype 1b HCV infections.
Aspartic Acid
;
Female
;
Fibrosis*
;
Genotype
;
Hepacivirus*
;
Hepatitis C*
;
Hepatitis C, Chronic
;
Hepatitis*
;
Humans
;
Liver Cirrhosis
;
Liver*
;
Male
;
RNA